Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.

WHO recommends computer-aided detection (CAD) in chest X-ray (CXR) for systematic screening of TB. Increased detection of individuals with high CAD score but without bacteriologically confirmed TB can be expected, requiring guidance on their clinical management. We followed participants of a TB prev...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Ruperez, Jacob Busang, Linda Mureithi, Kwame Shanaube, Eveline Klinkenberg, Thomas Gachie, James M Burnett, Barry Kosloff, Petra de Haas, Richard Hayes, Sarah Fidler, Ab Schaap, Sian Floyd, Helen Ayles, TREATS study team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLOS Global Public Health
Online Access:https://doi.org/10.1371/journal.pgph.0003787
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849419113388048384
author Maria Ruperez
Jacob Busang
Linda Mureithi
Kwame Shanaube
Eveline Klinkenberg
Thomas Gachie
James M Burnett
Barry Kosloff
Petra de Haas
Richard Hayes
Sarah Fidler
Ab Schaap
Sian Floyd
Helen Ayles
TREATS study team
author_facet Maria Ruperez
Jacob Busang
Linda Mureithi
Kwame Shanaube
Eveline Klinkenberg
Thomas Gachie
James M Burnett
Barry Kosloff
Petra de Haas
Richard Hayes
Sarah Fidler
Ab Schaap
Sian Floyd
Helen Ayles
TREATS study team
author_sort Maria Ruperez
collection DOAJ
description WHO recommends computer-aided detection (CAD) in chest X-ray (CXR) for systematic screening of TB. Increased detection of individuals with high CAD score but without bacteriologically confirmed TB can be expected, requiring guidance on their clinical management. We followed participants of a TB prevalence survey (TBPS) in Zambia and South Africa with a high CAD score but no bacteriologically confirmed TB over a median time of 9 months and assessed their clinical outcomes. At the TBPS participants with TB-suggestive symptoms or a CAD score ≥40 submitted two sputum samples for Xpert-Ultra testing, and, an additional sample was collected the next day for liquid culture and Xpert-ultra testing. Participants with a CAD score ≥70 and no bacteriologically confirmed TB were eligible for follow-up. At follow-up visit participants were asked about TB symptoms and treatment, underwent a repeat CXR with CAD, and those with either TB-suggestive symptoms or a CAD score ≥70 at follow-up submitted a sputum sample for Xpert-Ultra testing. A composite "clinical" outcome was defined based on changes in CAD-score and TB-suggestive symptoms between the TBPS and the follow-up. Of the 254 eligible TBPS participants 162 (65%) completed follow-up. Most of the participants self-reported previous TB (65% 105/162), were from Zambia (79%, 128/162,) and male (70%, 97/162). Overall, 43% (70/162) participants progressed clinically/remained radiologically abnormal and 6% (10/162) developed TB between the TBPS and the follow-up, with an overall TB incidence rate of 7% per year (95% CI: 3.8-13.3). Patients with high CAD score but no bacteriological confirmation may have had a past TB or other pulmonary lesions identified in the CXR, which may need to be investigated. Also, these participants may be at risk of progressing to TB over time and could benefit from a follow-up visit and from repeated assessment of symptoms and CXR.
format Article
id doaj-art-3ef05fc4681f488c94af46aefb3d6214
institution Kabale University
issn 2767-3375
language English
publishDate 2025-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLOS Global Public Health
spelling doaj-art-3ef05fc4681f488c94af46aefb3d62142025-08-20T03:32:15ZengPublic Library of Science (PLoS)PLOS Global Public Health2767-33752025-01-0156e000378710.1371/journal.pgph.0003787Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.Maria RuperezJacob BusangLinda MureithiKwame ShanaubeEveline KlinkenbergThomas GachieJames M BurnettBarry KosloffPetra de HaasRichard HayesSarah FidlerAb SchaapSian FloydHelen AylesTREATS study teamWHO recommends computer-aided detection (CAD) in chest X-ray (CXR) for systematic screening of TB. Increased detection of individuals with high CAD score but without bacteriologically confirmed TB can be expected, requiring guidance on their clinical management. We followed participants of a TB prevalence survey (TBPS) in Zambia and South Africa with a high CAD score but no bacteriologically confirmed TB over a median time of 9 months and assessed their clinical outcomes. At the TBPS participants with TB-suggestive symptoms or a CAD score ≥40 submitted two sputum samples for Xpert-Ultra testing, and, an additional sample was collected the next day for liquid culture and Xpert-ultra testing. Participants with a CAD score ≥70 and no bacteriologically confirmed TB were eligible for follow-up. At follow-up visit participants were asked about TB symptoms and treatment, underwent a repeat CXR with CAD, and those with either TB-suggestive symptoms or a CAD score ≥70 at follow-up submitted a sputum sample for Xpert-Ultra testing. A composite "clinical" outcome was defined based on changes in CAD-score and TB-suggestive symptoms between the TBPS and the follow-up. Of the 254 eligible TBPS participants 162 (65%) completed follow-up. Most of the participants self-reported previous TB (65% 105/162), were from Zambia (79%, 128/162,) and male (70%, 97/162). Overall, 43% (70/162) participants progressed clinically/remained radiologically abnormal and 6% (10/162) developed TB between the TBPS and the follow-up, with an overall TB incidence rate of 7% per year (95% CI: 3.8-13.3). Patients with high CAD score but no bacteriological confirmation may have had a past TB or other pulmonary lesions identified in the CXR, which may need to be investigated. Also, these participants may be at risk of progressing to TB over time and could benefit from a follow-up visit and from repeated assessment of symptoms and CXR.https://doi.org/10.1371/journal.pgph.0003787
spellingShingle Maria Ruperez
Jacob Busang
Linda Mureithi
Kwame Shanaube
Eveline Klinkenberg
Thomas Gachie
James M Burnett
Barry Kosloff
Petra de Haas
Richard Hayes
Sarah Fidler
Ab Schaap
Sian Floyd
Helen Ayles
TREATS study team
Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
PLOS Global Public Health
title Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
title_full Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
title_fullStr Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
title_full_unstemmed Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
title_short Clinical outcomes of participants of a TB prevalence survey with an abnormal chest X-ray but no evidence of TB disease after a median follow-up of 9 months in Zambia and South Africa.
title_sort clinical outcomes of participants of a tb prevalence survey with an abnormal chest x ray but no evidence of tb disease after a median follow up of 9 months in zambia and south africa
url https://doi.org/10.1371/journal.pgph.0003787
work_keys_str_mv AT mariaruperez clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT jacobbusang clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT lindamureithi clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT kwameshanaube clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT evelineklinkenberg clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT thomasgachie clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT jamesmburnett clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT barrykosloff clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT petradehaas clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT richardhayes clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT sarahfidler clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT abschaap clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT sianfloyd clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT helenayles clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica
AT treatsstudyteam clinicaloutcomesofparticipantsofatbprevalencesurveywithanabnormalchestxraybutnoevidenceoftbdiseaseafteramedianfollowupof9monthsinzambiaandsouthafrica